Fidelity Investments
NRXP icon

Fidelity Investments’s NRX Pharmaceuticals NRXP Stock Holding History

Fidelity Investments’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37
Closed -$76 – 5445
2025
Q1 		$76 Sell
37
-113
-75% -$318 ﹤0.01% 5132
2024
Q4 		$330 Buy
+150
New +$202 ﹤0.01% 5024
2024
Q2 		– Sell
-11
Closed -$52 – 5551
2024
Q1 		$52 Buy
+11
New +$51 ﹤0.01% 5027

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity Investments's NRXP Position: Q2 2025 in Review

Fidelity Investments sold out of NRX Pharmaceuticals (NRXP) in Q2 2025, closing a stake of 37 shares — an estimated $76 sold.

Fidelity Investments first reported a position in NRXP in Q1 2024 and held it in 3 quarters. The position peaked at $330 in Q4 2024. 25 funds tracked by Wall St. Rank hold NRXP as of Q2 2025.

  • Fidelity Investments reported no remaining NRX Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Fidelity Investments sold 37 NRX Pharmaceuticals shares in Q2 2025, an estimated $76.
  • Fidelity Investments first reported a position in NRX Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Fidelity Investments's NRX Pharmaceuticals position peaked at $330 in Q4 2024.
  • 25 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.